Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$28.12 USD

28.12
1,572,738

-0.16 (-0.57%)

Updated May 20, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (164 out of 248)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

DENTSPLY to Acquire OraMetrix, Boost CAD-CAM Dental Unit

The acquisition of OraMetrix is likely to bolster DENTSPLY's (XRAY) dental business.

    Gargi Seth headshot

    Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks

    The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.

      Here's Why You Should Steer Clear of DENTSPLY (XRAY) for Now

      DENTSPLY SIRONA (XRAY) faces foreign exchange woes and chances of margin decline in the quarters ahead.

        New Strong Sell Stocks for March 19th

        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

          DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4

          Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.

            Patterson Companies (PDCO) Q3 Earnings: What's in Store?

            Diverse product portfolio and strong veterinary business prospects to drive Patterson Companies (PDCO) in Q3. However, sluggishness in the Dental-Supply segment is a woe.

              Can Geographical Sales Aid DENTSPLY's (XRAY) Q4 Earnings?

              DENTSPLY (XRAY) anticipates lower regional sales to dent results in Q4. The company continues to focus on operational excellence.

                Patterson Companies' (PDCO) Dental Segment Shows Weakness

                Changing healthcare environment in the United States, unfavorable price movements and competitive dental products industry are posing challenges for Patterson Companies, Inc. (PDCO).

                  Align Teams Up with Exocad to Expand in Digital Scanning

                  Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.

                    DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                    DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.

                      Align Technology-Glidewell Dental Deal to Boost iTero Uptake

                      Align Technology (ALGN) progresses with deals to boost the Scanners and Services segment.

                        DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3

                        DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.

                          DENTSPLY (XRAY) Q3 Earnings Beat Estimates, Sales Rise Y/Y

                          DENTSPLY reported adjusted earnings of 70 cents per share, which came above the Zacks Consensus Estimate by 4 cents and was higher than earnings of 66 cents in the year-ago quarter.

                            Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?

                            In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.

                              DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                              DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

                                Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill

                                The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.

                                  New Strong Sell Stocks for September 12th

                                  Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                    New Strong Sell Stocks for August 16th

                                    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                      DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2

                                      DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.

                                        DENTSPLY (XRAY) Q2 Earnings Miss Estimates, Sales Fall Y/Y

                                        DENTSPLY reported adjusted earnings of 65 cents per share, which missed the Zacks Consensus Estimate by a penny and was lower than earnings of 76 cents in the year-ago quarter.

                                          4 Medical Product Stocks Likely to Top Q2 Earnings Estimates

                                          There are some powerful long-term tailwinds in the medical space.

                                            Why DENTSPLY (XRAY) Might Surprise This Earnings Season

                                            DENTSPLY (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                              Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?

                                              DENTSPLY Sirona's (XRAY) results are likely to be boosted by surging dental & healthcare consumables space in the yet-to-be-reported second quarter.

                                                Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?

                                                We expect second-quarter results of Flowserve (FLS) to gain traction from its strong operation model, solid productivity and geographical diversity.

                                                  Why an Earnings Beat is Likely for Waters Corp. (WAT) in Q2

                                                  Waters Corp.'s (WAT) dominant position in the biopharma end markets and thriving sales in emerging markets will likely help it gain traction in the second quarter.